|
C4 Therapeutics ، Inc. (CCCC) تقييم DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
C4 Therapeutics, Inc. (CCCC) Bundle
اكتشف C4 Therapeutics ، Inc. (CCCC) القيمة الحقيقية مع حاسبة DCF المتقدمة لدينا! اضبط الافتراضات الرئيسية ، واستكشف السيناريوهات المختلفة ، وقم بتقييم كيفية تأثير التغييرات على تقييم C4 Therapeutics ، Inc. (CCCC) - كل ذلك ضمن قالب Excel واحد.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.4 | 33.2 | 45.8 | 31.1 | 20.8 | 22.2 | 23.7 | 25.4 | 27.2 | 29.1 |
| Revenue Growth, % | 0 | 55.25 | 37.93 | -32.08 | -33.25 | 6.96 | 6.96 | 6.96 | 6.96 | 6.96 |
| EBITDA | -30.6 | -62.9 | -78.8 | -124.3 | -122.1 | -22.2 | -23.7 | -25.4 | -27.2 | -29.1 |
| EBITDA, % | -142.91 | -189.46 | -172.2 | -399.68 | -588.28 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.7 | 2.8 | 2.9 | 7.6 | 7.7 | 4.0 | 4.2 | 4.5 | 4.9 | 5.2 |
| Depreciation, % | 12.81 | 8.56 | 6.35 | 24.35 | 37.28 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 |
| EBIT | -33.3 | -65.7 | -81.7 | -131.9 | -129.8 | -22.2 | -23.7 | -25.4 | -27.2 | -29.1 |
| EBIT, % | -155.72 | -198.02 | -178.55 | -424.03 | -625.55 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 90.5 | 371.7 | 309.3 | 337.1 | 253.7 | 22.2 | 23.7 | 25.4 | 27.2 | 29.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.6 | 4.5 | 5.7 | 1.5 | 11.8 | 4.8 | 5.2 | 5.5 | 5.9 | 6.3 |
| Account Receivables, % | 21.62 | 13.51 | 12.48 | 4.74 | 56.85 | 21.84 | 21.84 | 21.84 | 21.84 | 21.84 |
| Inventories | .0 | .0 | .0 | -61.0 | .0 | -4.4 | -4.7 | -5.1 | -5.4 | -5.8 |
| Inventories, % | 0.00000467705 | 0 | 0 | -196.04 | 0 | -20 | -20 | -20 | -20 | -20 |
| Accounts Payable | 5.4 | 5.7 | 4.5 | 1.2 | 1.4 | 2.8 | 3.0 | 3.2 | 3.4 | 3.7 |
| Accounts Payable, % | 25.19 | 17.12 | 9.84 | 3.77 | 6.97 | 12.58 | 12.58 | 12.58 | 12.58 | 12.58 |
| Capital Expenditure | -1.3 | -.7 | -1.3 | -5.5 | -1.7 | -1.6 | -1.8 | -1.9 | -2.0 | -2.1 |
| Capital Expenditure, % | -6.31 | -1.96 | -2.79 | -17.67 | -8.23 | -7.39 | -7.39 | -7.39 | -7.39 | -7.39 |
| Tax Rate, % | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 | -0.97551 |
| EBITAT | -34.1 | -65.1 | -83.8 | -130.1 | -131.1 | -22.1 | -23.6 | -25.3 | -27.0 | -28.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -31.9 | -62.5 | -84.6 | -66.2 | -196.1 | -7.0 | -21.0 | -22.4 | -24.0 | -25.7 |
| WACC, % | 13.18 | 13.17 | 13.18 | 13.16 | 13.18 | 13.17 | 13.17 | 13.17 | 13.17 | 13.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -66.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -26 | |||||||||
| Terminal Value | -234 | |||||||||
| Present Terminal Value | -126 | |||||||||
| Enterprise Value | -193 | |||||||||
| Net Debt | -56 | |||||||||
| Equity Value | -137 | |||||||||
| Diluted Shares Outstanding, MM | 50 | |||||||||
| Equity Value Per Share | -2.76 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real C4 Therapeutics (CCCC) financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effects of your inputs on C4 Therapeutics' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for C4 Therapeutics, Inc. (CCCC).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Easily modify growth projections, capital expenditures, and discount rates relevant to C4 Therapeutics, Inc. (CCCC).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for C4 Therapeutics, Inc. (CCCC).
- Interactive Dashboard and Charts: Visual representations of key valuation metrics facilitate straightforward analysis for stakeholders.
How It Functions
- Download the Tool: Gain immediate access to the Excel-based C4 Therapeutics DCF Calculator.
- Enter Your Assumptions: Modify the yellow-highlighted cells for growth projections, WACC, profit margins, and additional parameters.
- Real-Time Calculations: The model automatically recalculates C4 Therapeutics’ intrinsic value.
- Explore Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Evaluate and Decide: Utilize the outcomes to inform your investment or financial assessments.
Why Choose This Calculator?
- User-Friendly Interface: Crafted for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your analysis needs.
- Real-Time Feedback: Witness immediate updates to C4 Therapeutics, Inc.'s (CCCC) valuation as you modify inputs.
- Preloaded Data: Comes equipped with C4 Therapeutics, Inc.'s (CCCC) actual financial metrics for swift evaluation.
- Relied Upon by Experts: Employed by investors and analysts for making well-informed decisions.
Who Should Use This Product?
- Investors: Gain insights into potential investments with advanced analytics tailored for C4 Therapeutics, Inc. (CCCC).
- Pharmaceutical Analysts: Streamline your research with comprehensive data on drug development and market strategies.
- Healthcare Consultants: Efficiently modify reports and presentations to meet client needs in the biotech sector.
- Biotech Enthusiasts: Enhance your knowledge of therapeutic innovations with case studies from C4 Therapeutics, Inc. (CCCC).
- Academics and Students: Utilize this resource as a hands-on tool for studying pharmaceutical business models and strategies.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to C4 Therapeutics, Inc. (CCCC).
- Real-World Data: C4 Therapeutics’ historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage tailored to C4 Therapeutics, Inc. (CCCC).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results relevant to C4 Therapeutics, Inc. (CCCC).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.